
    
      During the treatment period of the study, participants received treatment with
      ABT-450/ritonavir/ABT-267 and ABT-333 coadministered with RBV for either 12 or 24 weeks. Upon
      completing the treatment period or premature discontinuation of the treatment period,
      participants entered a 48-week post-treatment period.
    
  